In vivo quantification of the cerebral monoacylglycerol lipase using [18F]T-401

In vivo quantification of the cerebral monoacylglycerol lipase using [18F]T-401 - In vivo quantification of the cerebral monoacylglycerol lipase using [18F]T-401

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000031787

Enrollment

Registered

2018-04-01

Start date

2018-03-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Normal healthy controls

Interventions

[18F]T401 PET

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Healthy male

Exclusion criteria

Exclusion criteria: 1. Subjects who do not have ability to make informed consent. 2. Subjects with any psychiatric disorder or subjects with severe physical complication 3. Subjects who currently smokes 4. Subjects with any organic brain disorder 5. Subjects with metallic medical device in the body 6. Subjects with tattoo 7. Subjects with severe claustrophobia 8. Subjects with a history of allergy to heparin and local anesthetics. 9. Subjects who has participated in other study in recent 6 months 10. Subjects who has participated in blood donation in recent 12 weeks 11. Subjects who is considered to be inappropriate to participate in the study

Design outcomes

Primary

Measure	Time frame
Pharmacokinetics and distribution volume of[18F]T-401 in human brain. Effective dose of [18F]T-401 in human	—

Secondary

Measure	Time frame
Relationship between the density of MAGL and cognitive function	—

Countries

Japan

Contacts

Public ContactKeisuke Takahata

National Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Department of Functional Brain Imaging Research

takahata.keisuke@qst.go.jp81432063025

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026